Acadia Healthcare AI Stock Analysis
Want to see ACHC full AI Analyst Report?
Acadia Healthcare (ACHC) AI Stock Analysis
Acadia Healthcare
(NASDAQ:ACHC)
ACHC scores as moderately attractive overall, driven primarily by a strong, guidance-raising earnings outlook and improving cash generation, supported by constructive price trends. These positives are tempered by weak underlying profitability in the financial statements, higher leverage/negative ROE, and a negative P/E that limits valuation support.
Acadia Healthcare (ACHC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.53B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.79M
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 0.44
- Revenue Growth
- 4.47%
- EPS Growth
- -1156.09%
- Country
- US
- Employees
- 22,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Acadia Healthcare Business Overview & Revenue Model
Company Description
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient ps...
How the Company Makes Money
Acadia Healthcare makes money primarily by providing behavioral health treatment services and collecting reimbursement for patient care delivered across its facilities and programs. Key revenue streams and how they work: 1) Patient service revenue (p...
Acadia Healthcare Earnings Call Summary
The call was strongly positive. Acadia reported revenue, adjusted EBITDA, and adjusted EPS above expectations, generated $47 million of free cash flow, reduced debt by $63 million, raised full-year guidance for the third consecutive quarter, opened significant new capacity, and reported strong acute demand and improving CTC admissions. The main challenges were the New York Medicaid headwind, ongoing startup facility losses, flat sequential CTC revenue, lower commercial mix, shorter length of stay, and continued legal and revenue-cycle costs, but management described progress on each operational area and maintained a favorable outlook for 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Acadia raised guidance to revenue in a range of $3.44 billion-$3.46 billion, adjusted EBITDA in a range of $615 million-$625 million, adjusted EPS in a range of $1.70-$1.80, and operating cash flow in a range of $375 million-$400 million, while full-year CapEx is forecast in a range of $210 million-$230 million. The company expects approximately $60 million of incremental adjusted EBITDA from facilities opened in 2023, 2024, 2025, and 2026 in 2027 compared to 2026, supporting the previously discussed $200 million of incremental adjusted EBITDA relative to 2025; preliminary math projects startup facility losses declining from about $45 million to around $10 million, with break-even occupancy usually around 40%. Programs in Florida and Ohio could add more than $20 million in incremental EBITDA, but are not included in guidance ranges, and the company expects overall patient day growth to continue to be in that 3%-4% range.
Acadia Healthcare Financial Statement Overview
Summary
Financial statements are mixed: strong TTM revenue growth (~130%) is offset by materially deteriorated profitability (deep losses and compressed gross margin to ~11%). Leverage has risen (debt-to-equity ~1.24x) alongside very negative ROE (~-50%), raising risk, though TTM cash flow has improved with positive operating cash flow (~$235M) and positive free cash flow (~$91M).
Income Statement
34NegativeBalance Sheet
50NeutralCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.41B | 3.31B | 3.15B | 2.93B | 2.61B | 2.31B |
| Gross Profit | 549.27M | 583.44M | 711.98M | 682.61M | 2.51B | 2.22B |
| EBITDA | -660.74M | -737.83M | 607.84M | 189.11M | 561.67M | 459.47M |
| Net Income | -1.13B | -1.10B | 255.61M | -21.67M | 273.14M | 190.63M |
Balance Sheet | ||||||
| Total Assets | 5.55B | 5.53B | 5.96B | 5.36B | 4.99B | 4.77B |
| Cash, Cash Equivalents and Short-Term Investments | 163.31M | 133.24M | 76.31M | 100.07M | 97.65M | 133.81M |
| Total Debt | 2.50B | 2.65B | 2.09B | 1.51B | 1.53B | 1.64B |
| Total Liabilities | 3.30B | 3.39B | 2.77B | 2.47B | 2.09B | 2.19B |
| Stockholders Equity | 2.02B | 1.95B | 3.07B | 2.78B | 2.81B | 2.52B |
Cash Flow | ||||||
| Free Cash Flow | -23.86M | -439.91M | -560.69M | 38.21M | 84.42M | 129.67M |
| Operating Cash Flow | 235.19M | 131.90M | 129.69M | 462.34M | 380.57M | 374.48M |
| Investing Cash Flow | -219.20M | -547.58M | -736.48M | -397.22M | -305.83M | 1.02B |
| Financing Cash Flow | 28.62M | 472.61M | 583.02M | -62.70M | -110.90M | -1.64B |
Acadia Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACHC, the sentiment is Positive. The current price of 37.94 is above the 20-day moving average (MA) of 33.83, above the 50-day MA of 30.85, and above the 200-day MA of 27.13, indicating a bullish trend. The MACD of 2.34 indicates Negative momentum. The RSI at 69.79 is Neutral, neither overbought nor oversold. The STOCH value of 80.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACHC.
Acadia Healthcare Risk Analysis
Acadia Healthcare disclosed 55 risk factors in its most recent earnings report. Acadia Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAcadia Healthcare Peers Comparison
Overall Rating
HCSG78Outperform
UHS76Outperform
LFST72Outperform
HCA64Neutral
ACHC63Neutral
CYH44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $1.66B | 16.30 | 20.22% | ― | 3.96% | 175.90% | |
| 76Outperform | $11.07B | 8.01 | 19.54% | 0.42% | 8.00% | 13.14% | |
| 72Outperform | $5.39B | 75.26 | 4.82% | ― | 22.62% | ― | |
| 64Neutral | $104.69B | 16.52 | -100.45% | 0.61% | 5.82% | 16.59% | |
| 63Neutral | $3.53B | -3.04 | -57.05% | ― | 4.47% | -1156.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $284.87M | 7.57 | -2.51% | ― | -7.84% | -88.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare Company, Inc. | 37.94 | 23.60 | 164.57% | |
| CYH | Community Health Systems | 2.02 | -0.88 | -30.34% | |
| HCA | Hca Healthcare | 501.19 | 23.40 | 4.90% | |
| HCSG | Healthcare Services Group | 24.69 | 7.44 | 43.13% | |
| UHS | Universal Health Services | 191.98 | -34.97 | -15.41% | |
| LFST | Lifestance Health Group, Inc. | 14.17 | 7.99 | 129.29% |
Acadia Healthcare Corporate Events
Acadia Healthcare Reports Third-Quarter Results and Revenue Growth
PositiveOn November 4, 2026, Acadia reported third-quarter results for the period ended September 30, with revenue rising 5.1% to $895.3 million and adjusted EBITDA increasing 2% to $176.4 million. Net income attributable to Acadia fell 5% to $34.5 million,...
Acadia Healthcare Gains Preliminary Approval in Derivative Settlement
PositiveOn September 1, 2026, the U.S. District Court for the Middle District of Tennessee granted preliminary approval to a proposed settlement of stockholder derivative claims brought nominally on behalf of Acadia Healthcare against several current and for...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
